NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News

$5.05

+0.22 (+4.55%)

(As of 09/28/2023 ET)

Compare

Today's Range: $4.84
▼
$5.25
50-Day Range: $3.91
▼
$5.90
52-Week Range: $1.56
▼
$9.25

Volume: 77,096 shs
Average Volume: 130,943 shs
Market Capitalization: $114.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.60

Reviva Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 189.1% Upside
$14.60 Price Target
Short Interest: Bearish
6.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.39
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.41) to ($1.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

696th out of 969 stocks

Pharmaceutical Preparations Industry

328th out of 453 stocks

3.5

Analyst's Opinion

Consensus Rating
Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.60, Reviva Pharmaceuticals has a forecasted upside of 189.1% from its current price of $5.05.
Amount of Analyst Coverage
Reviva Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.49% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Reviva Pharmaceuticals has recently increased by 13.95%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVPH.

3.0

News and Social Media Coverage

News Sentiment
Reviva Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
8 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
4 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.06% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 24.09% of the stock of Reviva Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reviva Pharmaceuticals has a P/B Ratio of 8.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reviva Pharmaceuticals (NASDAQ:RVPH) Stock

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

RVPH Price History

30 days | 90 days | 365 days | Advanced Chart

RVPH Stock News Headlines

September 27, 2023 | msn.com

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER

September 26, 2023 | markets.businessinsider.com

Reviva Pharmaceuticals Holdings: A Promising Investment Based on Successful Brilaroxazine Schizophrenia Studies

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 25, 2023 | finance.yahoo.com

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

September 25, 2023 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $14.60 Consensus PT from Brokerages

September 23, 2023 | americanbankingnews.com

Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at Roth Capital

September 22, 2023 | finanznachrichten.de

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report on Bloomberg TV

September 22, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

September 29, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 22, 2023 | americanbankingnews.com

Roth Mkm Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)

September 20, 2023 | msn.com

Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation

September 20, 2023 | markets.businessinsider.com

Reviva Pharmaceuticals Holdings (RVPH) Receives a New Rating from Roth MKM

September 7, 2023 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 18, 2023 | finance.yahoo.com

RVPH: RECOVER Enrollment Complete

August 17, 2023 | finance.yahoo.com

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

August 16, 2023 | finance.yahoo.com

We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

August 14, 2023 | finance.yahoo.com

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

July 31, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

June 26, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)

June 26, 2023 | markets.businessinsider.com

Expert Ratings for Reviva Pharmaceuticals

June 26, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to be Added to Russell Microcap® Index

June 22, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

June 15, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June

June 9, 2023 | msn.com

Benchmark Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Speculative Buy Recommendation

June 8, 2023 | markets.businessinsider.com

Where Reviva Pharmaceuticals Stands With Analysts

May 25, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

May 22, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

See More Headlines

Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Company Calendar

Last Earnings: 8/14/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVPH
CUSIP: N/A
CIK: 1742927
Web: www.revivapharma.com
Phone: (408) 501-8881
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.60
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +189.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -306.16%
Return on Assets: -181.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.29
Quick Ratio: 1.29

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 8.42

Miscellaneous

Outstanding Shares: 22,650,000
Free Float: 15,388,000
Market Cap: $114.38 million
Optionable: Not Optionable
Beta: 0.11

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Laxminarayan Bhat Ph.D. (Age 58)
Founder, CEO, Pres & Director
Comp: $560k

Mr. Narayan Prabhu (Age 51)
Chief Financial Officer
Comp: $412.5k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVPH Stock - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings or view top-rated stocks.
What is Reviva Pharmaceuticals' stock price forecast for 2023?: 6 brokerages have issued 1 year price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price forecasts range from $10.00 to $18.00. On average, they anticipate the company's stock price to reach $14.60 in the next year. This suggests a possible upside of 189.1% from the stock's current price.
View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts.
How have RVPH shares performed in 2023?: Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of 2023. Since then, RVPH stock has increased by 18.8% and is now trading at $5.05.
View the best growth stocks for 2023 here.
When is Reviva Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our RVPH earnings forecast.

How were Reviva Pharmaceuticals' earnings last quarter?: Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.26.
What is Reviva Pharmaceuticals' stock symbol?: Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."
How do I buy shares of Reviva Pharmaceuticals?: Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reviva Pharmaceuticals' stock price today?: One share of RVPH stock can currently be purchased for approximately $5.05.
How much money does Reviva Pharmaceuticals make?: Reviva Pharmaceuticals (NASDAQ:RVPH) has a market capitalization of $114.38 million. The company earns $-24,340,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.
How can I contact Reviva Pharmaceuticals?: Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The official website for the company is www.revivapharma.com. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com.

This page (NASDAQ:RVPH) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial